Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.

ABSTRACT:

Objectives

Recent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response. Therefore, we performed this study to investigate whether immunotherapy-based neoadjuvant therapy is effective and safe for patients with resectable NSCLC.

Materials and methods

This open-label observational two-arm clinical study was performed at Shanghai Chest Hospital in China with patients who had resectable NSCLC and received two to three cycles of immunotherapy-based neoadjuvant therapy or neoadjuvant chemotherapy alone, followed by surgical resection. The primary endpoint was a major pathologic response (MPR). The secondary endpoints include a comp

SUBMITTER: Shen J 

PROVIDER: S-EPMC10560710 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature